<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00230061</url>
  </required_header>
  <id_info>
    <org_study_id>SNO-T-07-102</org_study_id>
    <nct_id>NCT00230061</nct_id>
  </id_info>
  <brief_title>Hepatitis B Vaccination in HIV-infected Persons</brief_title>
  <official_title>Randomised Open Label Clinical Trial of the Immune Response to Hepatitis B Vaccination in HIV-infected Persons.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stichting Nuts Ohra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <brief_summary>
    <textblock>
      In this study we compare the efficacy of two different HBV-vaccination schedules in
      HIV-infected persons concerning immune response and compliance. Short schedule: t=0,1,3 weeks
      and standard schedule: t=0,1,6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is known that HIV-infected persons are more prone to develop chronic hepatitis B infection
      when they get infected with this virus. After developing chronic hepatitis B these patients
      are more likely to get livercirrosis and hepatocellular carcinoma (Bodsworth et al.).

      Hepatitis B vaccination is available and the vaccine is about 95% protective in preventing
      immunocompetent persons from developing chronic hepatitis B infection (Lemon). The response
      on this vaccin is less effective in HIV-infected persons (Carne et al.). Furthermore there is
      a compliance problem in the standard scheme.

      In this study we compare the efficacy of two different HBV vaccination schedules in
      HIV-infected persons concerning immune response and compliance. A short schedule: t=0,1,3
      weeks, in which there are good results concerning immune response and compliance in
      immunocompetent persons (Saltog et al.) and the standard schedule: t=0,1,6 months. Patients
      not immune at week 28 will be offered boostervaccination. This consists of double doses at
      t=0,1,2 months.

      800 persons are needed to show non-inferiority with lower margin of 10% of the short schedule
      in comparison with the control group. Powercalculation is 80%. Randomization is stratified
      according to CD4 count(CD4 &lt;200, 200-500, &gt;500).

      The hypothesis of the study is a better compliance and a comparable immune response in the
      short schedule, through which persons will be protected against hepatitis B in an early
      stage.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of anti-Hbs titer after completing hepatitis B vaccination.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare response and compliance between two vaccination schedules: short and standard</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hepatitis B</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive

          -  Negative for HBsAg and anti-HBc

          -  18 years or older

        Exclusion Criteria:

          -  previous Hepatitis B vaccination

          -  current opportunistic infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodora EM de Vries-Sluijs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis. 1991 May;163(5):1138-40.</citation>
    <PMID>2019762</PMID>
  </reference>
  <reference>
    <citation>Sinicco A, Raiteri R, Sciandra M, Bertone C, Lingua A, Salassa B, Gioannini P. Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS. Scand J Infect Dis. 1997;29(2):111-5.</citation>
    <PMID>9181644</PMID>
  </reference>
  <reference>
    <citation>Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol. 1997 Jul;27(1):18-24.</citation>
    <PMID>9252068</PMID>
  </reference>
  <reference>
    <citation>Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med. 1997 Jan 16;336(3):196-204. Review.</citation>
    <PMID>8988900</PMID>
  </reference>
  <reference>
    <citation>Carne CA, Weller IV, Waite J, Briggs M, Pearce F, Adler MW, Tedder RS. Impaired responsiveness of homosexual men with HIV antibodies to plasma derived hepatitis B vaccine. Br Med J (Clin Res Ed). 1987 Apr 4;294(6576):866-8.</citation>
    <PMID>3105779</PMID>
  </reference>
  <reference>
    <citation>Keet IP, van Doornum G, Safary A, Coutinho RA. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS. 1992 May;6(5):509-10.</citation>
    <PMID>1535502</PMID>
  </reference>
  <reference>
    <citation>Wong EK, Bodsworth NJ, Slade MA, Mulhall BP, Donovan B. Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int J STD AIDS. 1996 Nov-Dec;7(7):490-4.</citation>
    <PMID>9116065</PMID>
  </reference>
  <reference>
    <citation>Bruguera M, Cremades M, Salinas R, Costa J, Grau M, Sans J. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol. 1992 Jan;14(1):27-30.</citation>
    <PMID>1532609</PMID>
  </reference>
  <reference>
    <citation>Rey D, Krantz V, Partisani M, Schmitt MP, Meyer P, Libbrecht E, Wendling MJ, Vetter D, Nicolle M, Kempf-Durepaire G, Lang JM. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine. 2000 Jan 18;18(13):1161-5.</citation>
    <PMID>10649616</PMID>
  </reference>
  <reference>
    <citation>Sasaki Md, Foccacia R, de Messias-Reason IJ. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine. 2003 Nov 7;21(31):4545-9.</citation>
    <PMID>14575766</PMID>
  </reference>
  <reference>
    <citation>Wilson CM, Ellenberg JH, Sawyer MK, Belzer M, Crowley-Nowick PA, Puga A, Futterman DC, Peralta L; Adolescent Medicine HIV/AIDS Research Network. Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. Reaching for Excellence in Adolescent Care and Health. J Adolesc Health. 2001 Sep;29(3 Suppl):123-9.</citation>
    <PMID>11530313</PMID>
  </reference>
  <reference>
    <citation>Rutstein RM, Rudy B, Codispoti C, Watson B. Response to hepatitis B immunization by infants exposed to HIV. AIDS. 1994 Sep;8(9):1281-4.</citation>
    <PMID>7802981</PMID>
  </reference>
  <reference>
    <citation>Scolfaro C, Fiammengo P, Balbo L, Madon E, Tovo PA. Hepatitis B vaccination in HIV-1-infected children: double efficacy doubling the paediatric dose. AIDS. 1996 Sep;10(10):1169-70.</citation>
    <PMID>8874636</PMID>
  </reference>
  <reference>
    <citation>Saltoğlu N, Inal AS, Tasova Y, Kandemir O. Comparison of the accelerated and classic vaccination schedules against Hepatitis B: three-week Hepatitis B vaccination schedule provides immediate and protective immunity. Ann Clin Microbiol Antimicrob. 2003 Nov 17;2:10.</citation>
    <PMID>14622443</PMID>
  </reference>
  <reference>
    <citation>Marchou B, Picot N, Chavanet P, Auvergnat JC, Armengaud M, Devilliers P, Cerisier JE, Marié FN, Excler JL. Three-week hepatitis B vaccination provides protective immunity. Vaccine. 1993 Nov;11(14):1383-5.</citation>
    <PMID>8310757</PMID>
  </reference>
  <reference>
    <citation>Nothdurft HD, Dietrich M, Zuckerman JN, Knobloch J, Kern P, Vollmar J, Sänger R. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine. 2002 Jan 15;20(7-8):1157-62.</citation>
    <PMID>11803077</PMID>
  </reference>
  <reference>
    <citation>Wright NM, Campbell TL, Tompkins CN. Comparison of conventional and accelerated hepatitis B immunisation schedules for homeless drug users. Commun Dis Public Health. 2002 Dec;5(4):324-6.</citation>
    <PMID>12564251</PMID>
  </reference>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2005</study_first_submitted>
  <study_first_submitted_qc>September 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2005</study_first_posted>
  <last_update_submitted>June 1, 2010</last_update_submitted>
  <last_update_submitted_qc>June 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Theodora EMS de Vries-Sluijs</name_title>
    <organization>ErasmusMC</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

